カテゴリ： Global Markets Direct, 医療/バイオ

神経性アセチルコリン受容体サブユニットアルファ4治療薬市場：パイプラインレビュー（2019年下半期）

◆英語タイトル：Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H2 2019
◆商品コード：GDATA20MY0443
◆発行会社（リサーチ会社）：Global Markets Direct
◆発行日：2019年12月27日
◆ページ数：59
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,500 ⇒換算￥367,500見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD7,000 ⇒換算￥735,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD10,500 ⇒換算￥1,102,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

 【レポートの概要】

Neuronal Acetylcholine Receptor Subunit Alpha 4 – Pipeline Review, H2 2019
Summary

According to the recently published report ‘Neuronal Acetylcholine Receptor Subunit Alpha 4 – Pipeline Review, H2 2019′; Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.

The report ‘Neuronal Acetylcholine Receptor Subunit Alpha 4 – Pipeline Review, H2 2019′ outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Smoking Cessation, Psychiatric Disorders, Alcohol Addiction, Major Depressive Disorder, Neurology and Nicotine Addiction.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Overview
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Companies Involved in Therapeutics Development
Assuage Pharmaceuticals Inc
H. Lundbeck AS
Jeil Pharmaceutical Co Ltd
Kyung Dong Co Ltd
Sopharma AD
Suven Life Sciences Ltd
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Drug Profiles
AP-202 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytisinicline – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JLP-1603 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-8001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNA4 and CHRNB2 for Neurological and Psychiatric disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-911 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varenicline tartrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varenicline tartrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Achieve Life Sciences announces completion of meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline smoking cessation phase 3 clinical development program
Oct 24, 2019: Achieve Life Sciences announces presentation of Cytisinicline data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
Sep 30, 2019: Achieve Life Sciences announces completion of maximum tolerated dose study
Sep 13, 2019: Achieve Life Sciences announces final phase 2b ORCA-1 trial data presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Sep 05, 2019: Achieve Life Sciences to host investor day on September 20th including roundtable discussion with smoking cessation medical experts and final data from the phase 2b ORCA-1trial
Jul 23, 2019: Achieve Life Sciences extends collaboration with the National Institutes of Health to advance the development of Cytisinicline for Smoking Cessation
Jun 21, 2019: Achieve Life Sciences announces Phase 2b ORCA-1 trial data accepted for oral presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Jun 11, 2019: Achieve Life Sciences announces statistically significant improvement in quit rates for simplified cytisinicline dosing schedule in phase 2b ORCA-1 dose-selection trial
May 30, 2019: Achieve announces patent granted in the U.S. for novel formulation of Cytisinicline
Apr 24, 2019: Achieve Life Sciences announces last subject, last visit completed in phase 2b ORCA-1 trial of Cytisinicline for Smoking Cessation
Apr 02, 2019: Achieve Life Sciences announces successful completion of the second and final DSMC review of phase 2b ORCA-1 trial of Cytisinicline for Smoking Cessation
Feb 22, 2019: FDA updates label for Chantix with data underscoring it’s not effective in children 16 and younger
Feb 22, 2019: Achieve announces final data from Cytisinicline phase I/II multi-dose, pharmacokinetic and pharmacodynamics (pk/pd) clinical study to be presented at Society for Research on Nicotine & Tobacco Annual Meeting
Feb 20, 2019: Achieve Life Sciences announces completion of enrollment in 254-subject phase 2b trial of Cytisinicline for smoking cessation
Dec 18, 2018: Achieve Announces Update on Cytisinicline Clinical Development Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Assuage Pharmaceuticals Inc, H2 2019
Pipeline by H. Lundbeck AS, H2 2019
Pipeline by Jeil Pharmaceutical Co Ltd, H2 2019
Pipeline by Kyung Dong Co Ltd, H2 2019
Pipeline by Sopharma AD, H2 2019
Pipeline by Suven Life Sciences Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

【掲載企業】

Assuage Pharmaceuticals Inc
H. Lundbeck AS
Jeil Pharmaceutical Co Ltd
Kyung Dong Co Ltd
Sopharma AD
Suven Life Sciences Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[神経性アセチルコリン受容体サブユニットアルファ4治療薬市場：パイプラインレビュー（2019年下半期）]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. 神経性アセチルコリン受容体サブユニットアルファ4治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0979 / Global Markets Direct / 2020年3月31日 / ...Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H1 2020 Summary According to the recently published report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H1 2020'; Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation...
  2. 神経性アセチルコリン受容体サブユニットベータ2治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0376 / Global Markets Direct / 2019年12月27日 / ...Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2019 Summary According to the recently published report 'Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2019'; Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Neuronal acetylcholine receptor subunit beta-2 is a protein encoded by the CHRNB2 gene. Acetylcholine binds to this receptor. This results in extensive change in conformation that affects all subunits and leads to opening of...
  3. 神経性アセチルコリン受容体サブユニットベータ2治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0968 / Global Markets Direct / 2020年3月31日 / ...Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H1 2020 Summary Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Neuronal acetylcholine receptor subunit...
  4. ムスカリン性アセチルコリン受容体M2治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0438 / Global Markets Direct / 2019年12月27日 / ...Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019 Summary According to the recently published report 'Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019'; Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 8 molecules. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression. The report 'Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019'...
  5. ムスカリン性アセチルコリン受容体M治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0465 / Global Markets Direct / 2019年12月27日 / ...Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2019 Summary Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 17 molecules. The latest report Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2019, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown...
  6. DNAジャイレースサブユニットB（EC5.99.1.3）治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0432 / Global Markets Direct / 2019年12月27日 / ...DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019 Summary DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019, outlays comprehensive information on the DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. DNA Gyrase Subunit B (EC 5.99.1.3) - DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. DNA gyrase has two subunits....
  7. サイクリン依存性キナーゼ7治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0345 / Global Markets Direct / 2019年12月27日 / ...Cyclin Dependent Kinase 7 - Pipeline Review, H2 2019 Summary Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Cell division protein kinase 7 is an enzyme that in humans is encoded by the CDK7 gene. CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. It phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and...
  8. ガンマアミノ酪酸受容体サブユニットガンマ2治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0322 / Global Markets Direct / 2019年12月27日 / ...Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H2 2019 Summary According to the recently published report 'Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H2 2019'; Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Gamma-aminobutyric acid receptor subunit gamma-2 is a protein encoded by the GABRG2 gene. It functions also as histamine receptor and mediates cellular...
  9. レット症候群治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0222 / Global Markets Direct / 2019年12月16日 / ...Rett Syndrome - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rett Syndrome - Pipeline Review, H2 2019, provides an overview of the Rett Syndrome (Central Nervous System) pipeline landscape. Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III, or the plateau and Stage IV, or the late motor deterioration stage. Symptoms include slowed growth, loss of normal movement and coordination, loss of communication abilities, breathing problems, pain,...
  10. プロバブルATP依存性RNAヘリカーゼDDX58治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0359 / Global Markets Direct / 2019年12月27日 / ...Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019 Summary According to the recently published report 'Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019'; Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆